Skip to main content
SpringerLink
Log in

Preventing end-stage renal disease: fact or fiction?

  • Chapter
Transplantation and Changing Management of Organ Failure

Part of the book series: Transplantation and Clinical Immunology ((TRAC,volume 32))

  • 55 Accesses

Abstract

Around the world, the number of patients with end-stage renal disease (ESRD) continues to grow, and with it the substantial morbidity and mortality associated with ESRD. Similarly, the already staggering cost of treatment for ESRD continues to increase. As a result, there has been a great amount of interest in finding ways to prevent ESRD, or at least slow the rate of progression of chronic renal insufficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bargman JM. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999; 70: S3–16.

    Article  PubMed  CAS  Google Scholar 

  2. Burgess E. Conservative treatment to slow deterioration of renal function: evidence-based recommendations. Kidney Int Suppl. 1999; 70: 517–25.

    Google Scholar 

  3. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroid-resistent focal segmental glomerulosclerosis. Kidney Int. 1999; 56: 2220–6.

    Article  PubMed  CAS  Google Scholar 

  4. Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995; 25: 862–75.

    Article  PubMed  CAS  Google Scholar 

  5. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J Am Soc Nephrol. 1995; 5: 1553–8.

    PubMed  CAS  Google Scholar 

  6. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995; 48: 1600–4.

    Article  PubMed  CAS  Google Scholar 

  7. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998; 9: 444–50.

    PubMed  CAS  Google Scholar 

  8. Branten AJ, Reichert LT, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Q J Med. 1998; 91: 359–66.

    Article  CAS  Google Scholar 

  9. Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int. 1995; 47: 1130–5.

    Article  PubMed  CAS  Google Scholar 

  10. Muirhead N. Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int Suppl. 1999; 70: 547–55.

    Google Scholar 

  11. Levin A. Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999; 70: 541–6.

    Google Scholar 

  12. Zimmerman SW, Moorthy AV, Dreher WH, Friedman A, Varanasi U. Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med. 1983; 75: 920–7.

    Article  PubMed  CAS  Google Scholar 

  13. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone–a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992; 6: 123–30.

    Article  PubMed  CAS  Google Scholar 

  14. Donadio JV Jr, Anderson CF, Mitchell JC HI et al. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med. 1984; 310: 1421–6.

    Article  PubMed  Google Scholar 

  15. Cattran DC, Cardella CJ, Roscoe JM et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int. 1985; 27: 436–41.

    Article  PubMed  CAS  Google Scholar 

  16. Zauner I, Bohler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multi-centre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol Dial Transplant. 1994; 9: 619–22.

    PubMed  CAS  Google Scholar 

  17. Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl. 1999; 70: 556–62.

    Google Scholar 

  18. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986; 26: 174–80.

    PubMed  CAS  Google Scholar 

  19. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353: 883–7.

    Article  PubMed  CAS  Google Scholar 

  20. Yoshikawa N, Ito H, Sakai T et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol. 1999; 10: 101–9.

    PubMed  CAS  Google Scholar 

  21. Woo KT, Edmondson RP, Yap HK et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol. 1987; 27: 56–64.

    PubMed  CAS  Google Scholar 

  22. Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol. 1991; 36: 60–6.

    PubMed  CAS  Google Scholar 

  23. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol. 1990; 34: 103–7.

    PubMed  CAS  Google Scholar 

  24. Lai KN, Lai FM, Li PK, Valiance-Owen J. Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J (Clin Res Ed). 1987; 295: 1165–8.

    Article  CAS  Google Scholar 

  25. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med. 1994; 331: 1194–9.

    Article  PubMed  Google Scholar 

  26. Donadio JV, Grande JP, Bergstralh EJ et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol. 1999; 10: 1772–7.

    PubMed  CAS  Google Scholar 

  27. Dillon J. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol. 1997; 8: 1739–44.

    PubMed  CAS  Google Scholar 

  28. Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999; 70: S33–40.

    Article  PubMed  CAS  Google Scholar 

  29. Johnson JP, Moore J Jr, Austin HA III, Balow JE, Antonovych TT, Wilson CB. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore). 1985; 64: 219–27.

    CAS  Google Scholar 

  30. Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997; 40: 2187–98.

    Article  PubMed  CAS  Google Scholar 

  31. Haubitz M, Schellong S, Gobel U et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998; 41: 1835–44.

    Article  PubMed  CAS  Google Scholar 

  32. Mauri JM, Gonzales MT, Poveda R. Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis. Plasma Ther Transfus Technol. 1985; 6: 587–91.

    Google Scholar 

  33. Glockner WM, Sieberth HG, Wichmann HE et al. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin Nephrol. 1988; 29: 1–8.

    PubMed  CAS  Google Scholar 

  34. Rifle G, Dechelette E. Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses. A prospective randomized trial of cyclophosphamide. Interim analysis. The French Cooperative Group. Prog Clin Biol Res. 1990; 337: 263–7.

    CAS  Google Scholar 

  35. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti- GBM antibodies. Kidney Int. 1991; 40: 757–63.

    Article  PubMed  CAS  Google Scholar 

  36. Cole E, Cattran D, Magil A, Greenwood C et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. 1992; 20: 261–9.

    PubMed  CAS  Google Scholar 

  37. Guillevin L, Lhote F, Cohen P et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995; 38: 1638–45.

    Article  PubMed  CAS  Google Scholar 

  38. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis. 1997; 29: 193–9.

    Article  PubMed  CAS  Google Scholar 

  39. Gourley MF, Austin HA III, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996; 125: 549–57.

    PubMed  CAS  Google Scholar 

  40. Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol. 1998; 37: 217–21.

    Article  PubMed  CAS  Google Scholar 

  41. Wallace DJ, Goldfinger D, Pepkowitz SH et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis. 1998; 13: 163–6.

    Article  PubMed  CAS  Google Scholar 

  42. Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol. 1998; 12: 101–4.

    Article  PubMed  CAS  Google Scholar 

  43. Van Damme-Lombaerts R, Proesmans W, Van Damme B et al. Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. J Pediatr. 1988; 113: 913–8.

    Article  PubMed  Google Scholar 

  44. Bobbio-Pallavicini E, Gugliotta L, Centurioni R et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997; 82: 429–35.

    PubMed  CAS  Google Scholar 

  45. Rizzoni G, Claris-Appiani A, Edefonti A et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr. 1988; 112: 284–90.

    Article  PubMed  CAS  Google Scholar 

  46. Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol. 1988; 2: 279–85.

    Article  PubMed  CAS  Google Scholar 

  47. Henon P. (Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study). Presse Med. 1991; 20: 1761–7.

    PubMed  CAS  Google Scholar 

  48. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991; 325: 393–7.

    Article  PubMed  CAS  Google Scholar 

  49. Wang PI, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet. 1993; 341: 1306–9.

    Article  PubMed  CAS  Google Scholar 

  50. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329: 977–86.

    Article  Google Scholar 

  51. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995; 47: 1703–20.

    Article  Google Scholar 

  52. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837–53.

    Article  Google Scholar 

  53. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998; 339: 69–75.

    Article  PubMed  CAS  Google Scholar 

  54. Fouque D, Laville M, Boissel JP, Chifet R, Labeeuw M, Zech PY. Controlled low protein diets in chronic renal insufficiency: meta-analysis. BMJ. 1992; 304: 216–20.

    Article  PubMed  CAS  Google Scholar 

  55. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med. 1996; 124: 627–32.

    PubMed  CAS  Google Scholar 

  56. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998; 31: 954–61.

    Article  PubMed  CAS  Google Scholar 

  57. Lowrie EG, Lew NL. Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. Semin Nephrol. 1992; 12: 276–83.

    PubMed  CAS  Google Scholar 

  58. Guijarro C, Massy ZA, Ma JZ, Wiederkehr M, Kasiske BL. Serum albumin and mortality after renal transplantation. Am J Kidney Dis. 1996; 27: 117–23.

    Article  PubMed  CAS  Google Scholar 

  59. Bergemann R, Wohler D, Weidmann P, Betzin J, Nawrath T. Verbesserte glucoseeinstellung and mikroalbuminurie/proteinurie bei diabetikern unter ACE-hemmer-behandlung. Schweiz Med Wochenschr. 1992; 122: 1369–76.

    PubMed  CAS  Google Scholar 

  60. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993; 118: 129–38.

    PubMed  CAS  Google Scholar 

  61. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant. 1995; 10: 1963–74.

    PubMed  CAS  Google Scholar 

  62. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995; 155: 1073–80.

    Article  PubMed  CAS  Google Scholar 

  63. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997; 127: 337–45.

    PubMed  CAS  Google Scholar 

  64. Jafar TH, Landa M, Schmid CH et al. The effect of angiotensin converting enzyme inhibitors (ACEI) on the progression of non-diabetic renal disease: interim results from a pooled analysis of randomized control trials (RCT). J Am Soc Nephrol. 1998:73A.

    Google Scholar 

  65. de Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet. 1999; 354: 352–53.

    Article  PubMed  Google Scholar 

  66. Fried L, Orchard T, Kasiske B. The effect of lipid reduction on renal disease progression: a meta-analysis. J Am Soc Nephrol. 1999; 10: 73A.

    Google Scholar 

  67. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis. 1998; 32 (5 Suppl. 3): S5–13.

    Article  PubMed  CAS  Google Scholar 

  68. Olsen NV, Ladefoged SD, Feldt-Rasmussen B, Fogh-Andersen N, Jordening H, Munck O. The effects of cimetidine on creatinine excretion, glomerular filtration rate and tubular function in renal transplant recipients. Scand J Clin Lab Invest. 1989; 49: 155–9.

    Article  PubMed  CAS  Google Scholar 

  69. Canadian Task Force on the Periodic Health Examination. Task Force Report on the Periodic Health Examination. Can Med Assoc J. 1979; 121: 1193–254.

    Google Scholar 

  70. US Preventative Services Task Force. Guide to Clinical Preventative Services: An Assessment of the Effectiveness of 169 Invertentions. Baltimore, MD: Williams & Wilkins, 1989.

    Google Scholar 

Download references

Authors
  1. Bertram L. Kasiske
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Pierre Cochat

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Kasiske, B.L. (2000). Preventing end-stage renal disease: fact or fiction?. In: Cochat, P. (eds) Transplantation and Changing Management of Organ Failure. Transplantation and Clinical Immunology, vol 32. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4118-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4118-5_8

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5802-5

  • Online ISBN: 978-94-011-4118-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation